Key Highlights

  • Sonic Healthcare Limited (ASX:SHL): FY26 underlying Revenue reached AUD 10.867 billion, representing growth of 13% year on year.
  • Underlying EBITDA increased 11% to AUD 1.933 billion, supported by a diversified diagnostics footprint.
  • Underlying net profit increased 17% to AUD 621 million, while underlying EPS rose 14% to 125.6 cents.
  • SHL completed a major German laboratory Acquisition and continued integration activity in Switzerland and Germany.
  • The company reported ongoing review of United States operations and growth in advanced diagnostics services.

Sonic Healthcare Limited (ASX:SHL) provides pathology, laboratory and diagnostic healthcare services. Its financial and operational review released on 20 August 2026 reported higher FY26 revenue, EBITDA and underlying profit. Growth included acquired businesses as well as operations in established laboratory networks. The company also discussed integration work in Europe, opportunities in advanced diagnostics and an operating review in the United States, illustrating that profitability improvements depend on both scale and execution.

Revenue and Earnings

SHL reported FY26 underlying revenue of AUD 10.867 billion, an increase of 13% year on year. Underlying EBITDA reached AUD 1.933 billion, up 11%, while underlying net profit increased 17% to AUD 621 million.

Underlying Earnings per share reached 125.6 cents, representing a 14% increase. The company distinguishes underlying from statutory measures in the release; comparisons need to retain that distinction when evaluating acquisition-related and other adjustments.

European Laboratory Expansion

SHL completed the acquisition of LADR in Germany during FY26. The transaction added operations to its European diagnostics network and increased the scale of service provision across a major market.

The company also reported progress capturing synergies from acquisitions in Germany and Switzerland. The timing and size of benefits remain dependent on laboratory integration, operational workflows and cost management. Acquisition-related growth can differ from the organic development of existing diagnostic services.

Operating Footprint and Diagnostics

The company’s FY26 materials described operations across nine countries and eleven markets, with hundreds of laboratories and a broad network of patient access points. This operating footprint supports a diverse range of pathology testing and specialist diagnostic services.

SHL also highlighted advanced diagnostics and its acquisition of Cairo Diagnostics. The wider service mix is relevant because technical capability, Demand from clinicians and reimbursement settings can influence the pace of revenue growth across different types of testing.

United States Review and Capital Management

The FY26 review noted that an operating assessment of United States activities remained in progress. The objective was to address profitability and returns, rather than reporting a completed earnings turnaround. Financial outcomes depend on the actions subsequently implemented.

SHL also reported the sale and leaseback of its Brisbane hub laboratory. Such capital-management actions affect asset ownership and financing arrangements but should not be interpreted as recurring laboratory revenue. The company stated a focus on improving Earnings Per Share and return on invested capital.

Key Insights

SHL’s FY26 review combined higher underlying revenue and profit with material acquisition and operational initiatives. European laboratory integration and advanced diagnostics provide additional operational context, while the United States review remains a workstream rather than a completed result. Future disclosures will need to distinguish acquired revenue, recurring diagnostic demand and the cost of integration.